ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team

  ARIAD Announces Appointment of European General Manager and Other Key
  Members of Leadership Team

 Ready for Anticipated Regulatory Approval and Launch of Iclusig^® in Europe
                                  this Year

Business Wire

CAMBRIDGE, Mass. & LAUSANNE, Switzerland -- February 21, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of
Jonathan E. Dickinson to the position of General Manager, ARIAD
Pharmaceuticals (Europe), Sàrl. Mr. Dickinson is a seasoned commercial
executive bringing more than 20 years of pharmaceutical-industry experience to
ARIAD, with special emphasis on global and pan-European leadership of several
important cancer medicines. Mr. Dickinson is responsible for leading ARIAD’s
European commercialization initiatives -- focused first on the anticipated
European approval and launch of Iclusig^® (ponatinib) in the third quarter of
2013 and subsequently on ARIAD’s other cancer medicines in development.

Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl
(Photo: Business Wire)

Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl
(Photo: Business Wire)

Mr. Dickinson joined ARIAD from Bristol-Myers Squibb, where he served for the
past three years as the European brand lead for ipilimumab, responsible for
the product’s European launch and commercialization in 29 countries.
Previously, during his 13-year tenure at Hoffmann-La Roche, Mr. Dickinson held
several key leadership positions, including lifecycle leader for capecitabine,
where he managed global marketing, clinical development, regulatory affairs
and manufacturing activities for the brand. At Roche, he had assignments both
in the U.S. and Switzerland that included leadership roles of Roche’s three
leading oncology medicines -- trastuzumab, rituximab, and capecitabine. Mr.
Dickinson began his career at Novartis, where he held commercial roles in its
oncology and endocrinology businesses, including medical sales, product
manager and business director in the United Kingdom.

Mr. Dickinson received his B.Sc. degree in Genetics and his M.B.A. degree from
the University of Nottingham. He is based at ARIAD’s European headquarters in
Lausanne, Switzerland and reports to Marty J. Duvall, senior vice president,
commercial operations of ARIAD.

“Jonathan is a proven leader with broad commercial and general management
experience promoting several of the most highly regarded oncology medicines
available today,” stated Harvey J. Berger, M.D., chairman and chief executive
officer of ARIAD. “His knowledge of the evolving European market and his
success in commercializing important cancer medicines throughout Europe and
globally will serve us well as we prepare for anticipated approval and
commercialization of Iclusig in the EU this year.”

Other Key European Appointments

Anna Casse – Head, Marketing and Sales. Ms. Casse joined ARIAD from Novartis,
where she served as head of the nephrology business unit in Germany. Prior to
this, as head of oncology marketing in Germany, she led the country launches
of nilotinib and everolimus. Ms. Casse also served as head of the Novartis
oncology business in Finland and oversaw global business development and
licensing for Novartis Opthalmics. Prior to her eight-year tenure at Novartis,
she spent four years in business development and strategic planning at Amgen
Europe. She also worked as a consultant at Arthur Little in the Benelux
countries. Ms. Casse has a B.S. from the University of Birmingham and an
M.B.A. at the INSEAD, Fontainebleau, France.

Anant Murthy, Ph.D. – Head, Pricing, Reimbursement and Access. Dr. Murthy
joined ARIAD from Celgene, where he was most recently the executive director
and head of global pricing and market access for hematology and oncology.
Previously, he expanded and led Celgene’s European pricing team to support the
launches of lenalidomide, azacitidine, and nab-paclitaxel across the EMEA
region. Prior to Celgene, Dr. Murthy worked in the reimbursement and health
economics team for the CRDM business of Medtronic, Inc. Dr. Murthy has a B.A.
from the University of Rochester, an M.S. in international health economics
from the London School of Economics, and a Ph.D. in international health
systems from the Johns Hopkins Bloomberg School of Public Health.

Kai C. Chan, M.D. - Head, Medical Affairs. Dr. Chan joined ARIAD from Genzyme
(Sanofi), where he was European head of medical affairs for transplant
oncology. Previously, Dr. Chan was with Johnson and Johnson as global medical
lead for bortezomib lung- cancer development, and with AstraZeneca in oncology
clinical research. Dr. Chan is a practicing surgeon at Wycombe Hospital in
High Wycombe, U.K. Dr. Chan has a M.B., Ch.B., M.D., and M.Sc. in Oncology
from the University of Manchester, a F.R.C.S. from the Royal College of
Surgeons of Edinburgh , and a Diploma in Pharmaceutical Medicine from the
University of Wales.

Thierry Bataillard – Head, Regulatory Affairs. Mr. Bataillard joined ARIAD
from Merck Serono, where he held leadership positions in regulatory affairs
within the oncology, endocrinology and diabetes businesses. He has a M.Sc.
from the Institute of Industrial Pharmacy at the University of Bordeaux and a
Pharm. D. from Claude Bernard University.

ARIAD has also hired the country managers for France, Germany, Italy and the
United Kingdom. Each of them brings over a decade of experience
commercializing cancer medicines.

“As we build an integrated global oncology company, the recruitment of this
outstanding European team clearly demonstrates our commitment to success,”
stated Marty J. Duvall, senior vice president, commercial operations of ARIAD.
“Led by Jonathan Dickinson, ARIAD will be fully prepared for the anticipated
EU approval and launch of Iclusig later this year.”


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

This press release contains “forward-looking statements” including, but not
limited to, potential regulatory approvals, new indications or labeling for,
or potential future sales of Iclusig. Forward-looking statements are based on
management's expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing and
performance to differ materially from those expressed or implied by such
statements. These risks and uncertainties include, but are not limited to,
preclinical data and early-stage clinical data that may not be replicated in
later-stage clinical studies, the costs associated with our research,
development, manufacturing and other activities, the conduct, timing and
results of pre-clinical and clinical studies of our product candidates, the
adequacy of our capital resources and the availability of additional funding,
and other factors detailed in the Company's public filings with the U.S.
Securities and Exchange Commission. The information contained in this press
release is believed to be current as of the date of original issue. The
Company does not intend to update any of the forward-looking statements after
the date of this document to conform these statements to actual results or to
changes in the Company's expectations, except as required by law.

Photos/Multimedia Gallery Available:



ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
For U.S. Media
Liza Heapes, 617-621-2315
For EU Media
Heather Grant, 44 (0)207 32 1873
Press spacebar to pause and continue. Press esc to stop.